iECURE
Derek Yuan, Ph.D. is a managing director at LYFE Capital and has been working there since the start of the investment team in 2018. He has been involved in multiple investments, including Pliant Therapeutics, Tempest Therapeutics, Cytek Biosciences, Immuneering, Kyverna, ImmuneOnco, and Aspen Neurosciences. Prior to LYFE Capital, Derek worked at Biotech Equity Research at Credit Suisse. He received his Ph.D. degree in chemical biology from the Rockefeller University and his B.S. in chemistry and biology from Tsinghua University.
This person is not in the org chart
This person is not in any offices
iECURE
1 followers
iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit. Our management team has extensive experience in executing global orphan drug and gene therapy clinical trials and successfully commercializing multiple products. We intend to leverage our team’s core strength in research and development strategy to identify what we believe to be the most suitable target and modality for our product candidates to address particular liver diseases. We are collaborating with the University of Pennsylvania’s Gene Therapy Program, or GTP, led by James M. Wilson, M.D., Ph.D., to utilize GTP’s world-class translational expertise and infrastructure, which has helped generate our initial pipeline of potential product candidates.